In contrast, BrM from melanoma have higher presence of CD4 and CD8 positive T cells, while BrM in breast cancer has a higher presence of neutrophils and macrophages, indicating that breast cancer BrM may show increased drug resistance compared with melanoma BrM (Klemm et al., 2020; Gonzalez et al., 2022). This evidence concerns the gene CD4 and breast cancer.